TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men aged 18-55 yrs.~* Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the McDonald Criteria.~* Expanded Disability Status Scale (EDSS) between 0-5, inclusive.~Exclusion Criteria:~* Relapse episode of MS within 2 weeks of enrollment.~* Primary progressive MS without a relapsing component.~* Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying agents up to 6 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): None
- PF-06342674 1.5 mg/kg (Type: EXPERIMENTAL): None
- PF-06342674 6.0 mg/kg (q2 Weeks) (Type: EXPERIMENTAL): None
- PF-06342674 6.0 mg/kg (q1 Week) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients undergoing whipple procedure with preoperative assignment as low risk for leakage from the pancreaticojejunal anastomosis.~* Signed informed consent.~Exclusion Criteria:~* High and intermediate risk pancreaticojejunal anastomosis. Unwillingness to participate.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Whipple procedure (Type: ACTIVE_COMPARATOR): Conventional Whipple procedure
- Subtotal gastrectomy added to whipple procedure. (Type: EXPERIMENTAL): Subtotal gastrectomy added to Whipple procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-Onset Multiple Sclerosis (POMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of Pediatric-Onset MS (\<18 years) according to the 2017 revised McDonald criteria (relapsing-remitting)~* Expanded Disability Status Scale (EDSS) ≤ 5.0~* Relapse free for the past 30 days (including no corticosteroids)~* No contraindications to physical activity, including pregnancy~* Participant and parent (if between 15 and 18 years of age) written informed consent.~Exclusion Criteria:~* History of visual provoked seizures~* EDSS \> 5.0

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Exercise Group (Type: EXPERIMENTAL): None
- Control Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* coronary artery diseases which require coronary angiography or percutaneous coronary intervention~* primary hypertension (systolic blood pressure 140-180mmHg within one month)~Exclusion Criteria:~* severe hypertension~* secondary hypertension~* treated with more than three antihypertensive drugs~* left main trunk trunk coronary artery disease~* moderate heart failure~* severe valvular disease~* liver dysfunction renal dysfunction (Cr\>=2.0mg/dl) Pregnant or nursing women severe arrhythmia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- intensive blood pressure control (Type: ACTIVE_COMPARATOR): systolic blood pressure less than 120 mmHg
- standard blood pressure control (Type: ACTIVE_COMPARATOR): systolic blood pressure less than 140 mmHg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nesiritide and Renal Function After the Total Artificial Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Implanted with a total artificial heart (CardioWest) or Left ventricular assist device (HeartMate II)~* Age \> 18 years~Exclusion Criteria:~* Previous calcineurin inhibitor (CNI) exposure~* Hemodialysis prior to device implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Total Artificial Heart (Type: EXPERIMENTAL): Nesiritide
- Total Artificial Heart: Placebo (Type: PLACEBO_COMPARATOR): Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
- LVAD: Nesiritide (Type: ACTIVE_COMPARATOR): Active arm of the LVAD group
- LVAD: Placebo (Type: PLACEBO_COMPARATOR): Control arm for subjects receiving LVAD and randomized to placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Each subject must meet the following criteria to be enrolled in this study:~1. The subject is male.~2. The subject is \<7 years of age.~3. The subject has had or is scheduled for ENT surgery for any of the following, alone or in combination: adenoidectomy, tonsillectomy, and tympanostomy.~4. The subject has record of previous surgical repair or presence of inguinal and/or umbilical hernia.~5. The subject's parent(s) or the subject's legally authorized representative(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from the study:~1. The subject has a current confirmed diagnosis of any MPS disorder.~2. The subject was born prematurely (defined as born before 37 weeks gestation).~3. The subject has received a blood transfusion within the past 6 weeks.~4. The subject has received a bone marrow transplant.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Analysis population (Type: None): All subjects enrolled in the study who meet the eligibility criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PureGen: Radiographic Analysis of Fusion for ACDF

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Persistent neck and/or arm pain consistent to symptomatic cervical degenerative disc disease~* Moderate Neck Disability Index~* Unresponsive to conservative treatment for at least 6 weeks~Exclusion Criteria:~* More than 4 levels requiring surgical treatment~* Prior failed fusion surgery at the index level(s)~* Systemic or local infection in the disc or cervical spine, past or present~* Active systemic disease~* Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing~* Known or suspected history of alcohol and/or drug abuse~* Involved in pending litigation or worker's compensation relating to the spine~* Pregnant or plans to become pregnant during the duration of the study~* Insulin-dependent diabetes mellitus~* Life expectancy less than study duration~* Any significant psychological disturbance that in the opinion of the Investigator could impair consent process or ability to complete self-assessment questionnaires~* BMI greater than 40~* Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs~* Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cervical Degenerative Disc Disease (Type: None): Subjects suffering from symptoms of cervical degenerative disc disease in one to four contiguous levels between C3 and T1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- All pediatric patient requiring Warfarin therapy.~Exclusion Criteria:~1. Subjects older then 18 year of age.~2. Pregnant subjects.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cognitus & Moi: a New Cognitive Remediation Tool

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with intellectual deficiency (5-13 years) (40 \< total IQ \< 75) with or without autism spectrum disorders~* Native French speaker~* Clinically stable~* Parental consent~Exclusion Criteria:~* visual or auditory disorder~* history of neurological illness or trauma~* Absence of language

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Cognitus and Me (Type: EXPERIMENTAL): Cognitus \& Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
- control group (Type: ACTIVE_COMPARATOR): the control management that involves fine motor skills and research computer information,management control is usually done

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hepatocellular carcinoma diagnosis according to Barcelona Clinic Liver Cancer (BCLC) staging and European Association for Study of Liver (EASL) criteria or histologically confirmed diagnosis (biopsy).~* Patients with untreated hepatocellular carcinoma, not suitable for curative treatment and having an anti-angiogenic treatment.~* Patients with no contra-indication to sorafenib treatment~* The previous treatment with surgery, chemo-embolization, radiofrequency, or conformal radiotherapy are not contra-indications to the inclusion~* Patients agreeing to participate (signed inform consent)~Exclusion Criteria:~* Patients with contra-indication to sorafenib treatment~* MRI contra-indication: ferromagnetic material, pacemaker, intraocular foreign bodies, claustrophobia, creatinine clearance below 30 ml / min by Modification of Diet in Renal Disease (MDRD) method~* True allergy to gadobenate dimeglumine~* Patients suffering from acute renal failure or chronic severe (GFR \<30 ml/min/1, 73 m²) and patients suffering from acute renal failure (regardless of severity) due to an hepatorenal syndrome~* Pregnancy or breast-feeding~* Refusal to sign the informed consent~* Patient has already been included in another study that could interfere with the results of the study. - Patients not affiliated to either the French social security system or an European health insurance.~* All persons deprived of liberty by a judicial or administrative law, patients hospitalized without consent under Articles L. 3212-1 and L. 3213-1 which are not covered by the provisions of Article L. 1121-8

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liver Perfusion MRI (Type: EXPERIMENTAL): liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women at \> 24 weeks gestation who are admitted in labor or admitted for induction of labor at Mount Sinai Hospital~Exclusion Criteria:~* Allergy to chlorhexidine~* Unplanned or emergency cesarean section~* Women at \<24 weeks gestation~* Estimated fetal weight \<500 grams~* Fetal face presentation regardless of gestational age.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorhexidine gluconate vaginal scrub and cloth (Type: EXPERIMENTAL): Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
- Standard Treatment (Type: ACTIVE_COMPARATOR): Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. is anticipated to be hospitalized for the duration of treatment.~2. is ≥22 years of age or their legally authorized representative is able to provide informed consent.~3. has a full thickness wound (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) measuring ≥4cm in length and ≥4cm in width (before removal of eschar at the bedside) excluding undermining/tunneling.~4. has, in the opinion of the investigator, no more than 2/3 of the visible wound bed surface area considered to be clean, healthy, and viable. If eschar is present at baseline, it must be removed by bedside debridement prior to assessing the percentage of clean, healthy, and viable wound bed.~5. has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) and is willing to take precautionary measures to prevent pregnancy during the duration of the study (up to 9 days).~Exclusion Criteria:~1. has been diagnosed with malignancy in the wound.~2. has untreated osteomyelitis.~3. has an untreated systemic infection.~4. has active cellulitis in the peri wound area.~5. has a known allergy or hypersensitivity to study materials: dressing and/or dressing components such as acrylic adhesives or polyurethane.~6. has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.~7. has had radiation directly to the wound.~8. has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.~9. has eschar in the wound that cannot be removed by beside or sharp and/or mechanical debridement.~10. is participating in another interventional clinical trial for the duration of the study.~11. has unexplored fistulas in the wound or fistulas in the wound that connect to other body cavities.~12. has inadequate hemostasis at the wound site, as determined by the investigator.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antiretroviral-naive patients with HIV-1 infection~* not more than 2 loose stools per day or any preexisting or emerging medical condition that would interfere with the evaluation of therapeutic response of the study drug~* No antidiarrheal medication within 7 days prior to entry~Exclusion Criteria:~* Greater than or equal to 2 loose stools per day lasting 2 or more days within 7 days prior to study entry~* Bloody stools within 7 days prior to study entry~* Any unstable or severe intercurrent medical condition, including active opportunistic infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of TRAVATAN in Subjects With Iris Pigmentation Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension;~* Has experienced an iris pigmentation change while dosing with TRAVATAN;~* Currently dosing with TRAVATAN;~* Other protocol-defined inclusion criteria may apply.~Exclusion:~* Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension;~* Not currently using TRAVATAN;~* Females of childbearing potential if pregnant, breast-feeding, or not using highly effective birth control measures;~* History of any severe ocular pathology (including severe dry eye);~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRAVATAN (Type: None): Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy